The IL-12–expressing self-replicating mRNA STX-001 showed a favorable therapeutic window at 100 µg, with regression in both injected and non-injected lesions.
|Videos|June 29, 2017
Dr. Ascierto on Sequencing of Targeted Therapies for Melanoma
Author(s)Paolo A. Ascierto, MD
Paolo A. Ascierto, MD, National Tumour Institutue “Fondazione G. Pascale,” Unit of Melanoma, Naples, Italy, discusses the sequencing of targeted therapies for patients with melanoma.
Advertisement
Paolo A. Ascierto, MD, National Tumour Institutue “Fondazione G. Pascale,” Unit of Melanoma, Naples, Italy, discusses the sequencing of targeted therapies for patients with melanoma.
There are several clinical trials investigating the sequencing of targeted therapies, explains Ascierto. There is a particular trial looking at the sequencing of the encorafenib and binimetinib combination, nivolumab (Opdivo) and ipilimumab (Yeroy) combination, and a third arm of immunotherapy in between targeted therapy agents.
<<<
Advertisement
Related to this article
Most of the survival time accrued with RP1 plus nivolumab in the IGNYTE trial was spent in good health among patients with advanced melanoma after anti–PD-1 therapy.
VET3-TGI produced responses in injected and non-injected lesions without dose-limiting toxicities in the phase 1/1b STEALTH-001 trial.
EVX-01 plus pembrolizumab generated sustained neoantigen-specific T-cell responses in advanced melanoma.
Experts break down key melanoma data and trends from the 2026 ESMO Congress.
Rocbrutinib plus chemoimmunotherapy led to complete responses in patients with untreated B-cell lymphomas.
Many patients with BRAF-altered pediatric low-grade glioma stayed off therapy after planned tovorafenib cessation in the 4-year FIREFLY-1 update.
Sarah Goldberg, MD, MPH, details how clinicians can choose among frontline regimens, act on resistance mechanisms, and incorporate ADCs and newer agents across the spectrum of EGFR-mutated NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
Vorasidenib Elicits Early Metabolic Responses in IDH-Mutant Glioma
2
Cross Currents: New Frontiers in ADC Therapy for Breast Cancer
3
Mirdametinib Deepens Responses in NF1-Associated Plexiform Neurofibroma
4
Dr Forde on Selecting Neoadjuvant and Perioperative Immunotherapy in Resectable NSCLC
5